Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

T-Cell Subsets (TCM, TEM, TEMRA) and Poly-Functional Immune Response in Patients with Human Immunodeficiency Virus (HIV) Infection and Different T-CD4 Cell Response.

Meraviglia S, Di Carlo P, Pampinella D, Guadagnino G, Presti EL, Orlando V, Marchetti G, Dieli F, Sergi C.

Ann Clin Lab Sci. 2019 Sep;49(4):519-528.

PMID:
31471343
2.

Γδ T Cell-Based Immunotherapy in Melanoma: State of the Art.

Toia F, Di Stefano AB, Meraviglia S, Lo Presti E, Pirrello R, Rinaldi G, Fulfaro F, Dieli F, Cordova A.

J Oncol. 2019 May 23;2019:9014607. doi: 10.1155/2019/9014607. eCollection 2019. Review.

3.

γδ cell-based immunotherapy for cancer.

Lo Presti E, Corsale AM, Dieli F, Meraviglia S.

Expert Opin Biol Ther. 2019 Sep;19(9):887-895. doi: 10.1080/14712598.2019.1634050. Epub 2019 Jun 23.

PMID:
31220420
4.

Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRVδ1 and TCRVδ2 γδ T lymphocytes.

Pizzolato G, Kaminski H, Tosolini M, Franchini DM, Pont F, Martins F, Valle C, Labourdette D, Cadot S, Quillet-Mary A, Poupot M, Laurent C, Ysebaert L, Meraviglia S, Dieli F, Merville P, Milpied P, Déchanet-Merville J, Fournié JJ.

Proc Natl Acad Sci U S A. 2019 Jun 11;116(24):11906-11915. doi: 10.1073/pnas.1818488116. Epub 2019 May 22.

PMID:
31118283
5.

Characterization of human infiltrating and circulating gamma-delta T cells in prostate cancer.

Vella M, Coniglio D, Abrate A, Scalici Gesolfo C, Lo Presti E, Meraviglia S, Serretta V, Simonato A.

Investig Clin Urol. 2019 Mar;60(2):91-98. doi: 10.4111/icu.2019.60.2.91. Epub 2019 Feb 26.

6.

Characterization of γδ T Cells in Intestinal Mucosa From Patients With Early-Onset or Long-Standing Inflammatory Bowel Disease and Their Correlation With Clinical Status.

Lo Presti E, Di Mitri R, Mocciaro F, Di Stefano AB, Scibetta N, Unti E, Cicero G, Pecoraro G, Conte E, Dieli F, Meraviglia S.

J Crohns Colitis. 2019 Jul 25;13(7):873-883. doi: 10.1093/ecco-jcc/jjz015.

PMID:
30689780
7.

Immunomodulation in Vascularized Composite Allotransplantation: What Is the Role for Adipose-Derived Stem Cells?

Pappalardo M, Montesano L, Toia F, Russo A, Di Lorenzo S, Dieli F, Moschella F, Leto Barone AA, Meraviglia S, Di Stefano AB.

Ann Plast Surg. 2019 Feb;82(2):245-251. doi: 10.1097/SAP.0000000000001763.

PMID:
30628936
8.

γδ T Cells and Tumor Microenvironment: From Immunosurveillance to Tumor Evasion.

Lo Presti E, Pizzolato G, Corsale AM, Caccamo N, Sireci G, Dieli F, Meraviglia S.

Front Immunol. 2018 Jun 15;9:1395. doi: 10.3389/fimmu.2018.01395. eCollection 2018. Review.

9.

γδ cells and tumor microenvironment: A helpful or a dangerous liason?

Lo Presti E, Di Mitri R, Pizzolato G, Mocciaro F, Dieli F, Meraviglia S.

J Leukoc Biol. 2018 Mar;103(3):485-492. doi: 10.1002/JLB.5MR0717-275RR. Epub 2017 Dec 14. Review.

PMID:
29345336
10.

Current Advances in γδ T Cell-Based Tumor Immunotherapy.

Lo Presti E, Pizzolato G, Gulotta E, Cocorullo G, Gulotta G, Dieli F, Meraviglia S.

Front Immunol. 2017 Oct 27;8:1401. doi: 10.3389/fimmu.2017.01401. eCollection 2017. Review.

11.

Distinctive features of tumor-infiltrating γδ T lymphocytes in human colorectal cancer.

Meraviglia S, Lo Presti E, Tosolini M, La Mendola C, Orlando V, Todaro M, Catalano V, Stassi G, Cicero G, Vieni S, Fourniè JJ, Dieli F.

Oncoimmunology. 2017 Jul 13;6(10):e1347742. doi: 10.1080/2162402X.2017.1347742. eCollection 2017.

12.

Clonal expansion shapes the human Vδ1T cell receptor repertoire.

Meraviglia S, Dieli F.

Cell Mol Immunol. 2018 Feb;15(2):96-98. doi: 10.1038/cmi.2017.66. Epub 2017 Jul 24. No abstract available.

13.

IL4 Primes the Dynamics of Breast Cancer Progression via DUSP4 Inhibition.

Gaggianesi M, Turdo A, Chinnici A, Lipari E, Apuzzo T, Benfante A, Sperduti I, Di Franco S, Meraviglia S, Lo Presti E, Dieli F, Caputo V, Militello G, Vieni S, Stassi G, Todaro M.

Cancer Res. 2017 Jun 15;77(12):3268-3279. doi: 10.1158/0008-5472.CAN-16-3126. Epub 2017 Apr 11.

14.

Squamous Cell Tumors Recruit γδ T Cells Producing either IL17 or IFNγ Depending on the Tumor Stage.

Lo Presti E, Toia F, Oieni S, Buccheri S, Turdo A, Mangiapane LR, Campisi G, Caputo V, Todaro M, Stassi G, Cordova A, Moschella F, Rinaldi G, Meraviglia S, Dieli F.

Cancer Immunol Res. 2017 May;5(5):397-407. doi: 10.1158/2326-6066.CIR-16-0348. Epub 2017 Mar 28.

15.

Activation and selective IL-17 response of human Vγ9Vδ2 T lymphocytes by TLR-activated plasmacytoid dendritic cells.

Lo Presti E, Caccamo N, Orlando V, Dieli F, Meraviglia S.

Oncotarget. 2016 Sep 20;7(38):60896-60905. doi: 10.18632/oncotarget.11755.

16.

Skewed Differentiation of Circulating Vγ9Vδ2 T Lymphocytes in Melanoma and Impact on Clinical Outcome.

Toia F, Buccheri S, Anfosso A, Moschella F, Dieli F, Meraviglia S, Cordova A.

PLoS One. 2016 Feb 25;11(2):e0149570. doi: 10.1371/journal.pone.0149570. eCollection 2016.

17.

γδ T cell-based anticancer immunotherapy: progress and possibilities.

Meraviglia S, Lo Presti E, Dieli F, Stassi G.

Immunotherapy. 2015;7(9):949-51. doi: 10.2217/imt.15.68. Epub 2015 Aug 27. Review. No abstract available.

PMID:
26569071
18.

A Risk Score Derived from the Analysis of a Cluster of 27 Serum Inflammatory Cytokines to Predict Long Term Outcome in Patients with Acute Myocardial Infarction: a Pilot Study.

Novo G, Bellia C, Fiore M, Bonomo V, Pugliesi M, Giovino M, Sasso BL, Meraviglia S, Assennato P, Novo S, Dieli F, Ciaccio M.

Ann Clin Lab Sci. 2015 Summer;45(4):382-90.

PMID:
26275688
19.

Tumor-Infiltrating γδ T Lymphocytes: Pathogenic Role, Clinical Significance, and Differential Programing in the Tumor Microenvironment.

Lo Presti E, Dieli F, Meraviglia S.

Front Immunol. 2014 Nov 24;5:607. doi: 10.3389/fimmu.2014.00607. eCollection 2014. Review.

20.

γδ T cells as a potential tool in colon cancer immunotherapy.

Ramutton T, Buccheri S, Dieli F, Todaro M, Stassi G, Meraviglia S.

Immunotherapy. 2014;6(9):989-99. doi: 10.2217/imt.14.59. Review.

PMID:
25341120
21.

Combining conventional chemotherapy and γδ T cell-based immunotherapy to target cancer-initiating cells.

Todaro M, Meraviglia S, Caccamo N, Stassi G, Dieli F.

Oncoimmunology. 2013 Sep 1;2(9):e25821. Epub 2013 Jul 29.

22.

Chemotherapy sensitizes colon cancer initiating cells to Vγ9Vδ2 T cell-mediated cytotoxicity.

Todaro M, Orlando V, Cicero G, Caccamo N, Meraviglia S, Stassi G, Dieli F.

PLoS One. 2013 Jun 6;8(6):e65145. doi: 10.1371/journal.pone.0065145. Print 2013.

23.

Distribution, function and predictive value of tumor-infiltrating γδ T lymphocytes.

Dieli F, Stassi G, Todaro M, Meraviglia S, Caccamo N, Cordova A.

Oncoimmunology. 2013 Apr 1;2(4):e23434.

24.

Characterization of human γδ T lymphocytes infiltrating primary malignant melanomas.

Cordova A, Toia F, La Mendola C, Orlando V, Meraviglia S, Rinaldi G, Todaro M, Cicero G, Zichichi L, Donni PL, Caccamo N, Stassi G, Dieli F, Moschella F.

PLoS One. 2012;7(11):e49878. doi: 10.1371/journal.pone.0049878. Epub 2012 Nov 26.

25.

Mechanisms underlying lineage commitment and plasticity of human γδ T cells.

Caccamo N, Todaro M, Sireci G, Meraviglia S, Stassi G, Dieli F.

Cell Mol Immunol. 2013 Jan;10(1):30-4. doi: 10.1038/cmi.2012.42. Epub 2012 Oct 22. Review.

26.

Role of exosomes released by chronic myelogenous leukemia cells in angiogenesis.

Taverna S, Flugy A, Saieva L, Kohn EC, Santoro A, Meraviglia S, De Leo G, Alessandro R.

Int J Cancer. 2012 May 1;130(9):2033-43. doi: 10.1002/ijc.26217. Epub 2011 Aug 8.

27.

Differentiation, phenotype, and function of interleukin-17-producing human Vγ9Vδ2 T cells.

Caccamo N, La Mendola C, Orlando V, Meraviglia S, Todaro M, Stassi G, Sireci G, Fournié JJ, Dieli F.

Blood. 2011 Jul 7;118(1):129-38. doi: 10.1182/blood-2011-01-331298. Epub 2011 Apr 19.

PMID:
21505189
28.

γδ T cells cross-link innate and adaptive immunity in Mycobacterium tuberculosis infection.

Meraviglia S, El Daker S, Dieli F, Martini F, Martino A.

Clin Dev Immunol. 2011;2011:587315. doi: 10.1155/2011/587315. Epub 2011 Jan 5. Review.

29.

Immunotherapy targeting colon cancer stem cells.

Iovino F, Meraviglia S, Spina M, Orlando V, Saladino V, Dieli F, Stassi G, Todaro M.

Immunotherapy. 2011 Jan;3(1):97-106. doi: 10.2217/imt.10.87. Review.

PMID:
21174560
30.

Optimizing tumor-reactive γδ T cells for antibody-based cancer immunotherapy.

Meraviglia S, Caccamo N, Guggino G, Tolomeo M, Siragusa S, Stassi G, Dieli F.

Curr Mol Med. 2010 Nov;10(8):719-26. Review.

PMID:
20937023
31.

Partial and ineffective activation of V gamma 9V delta 2 T cells by Mycobacterium tuberculosis-infected dendritic cells.

Meraviglia S, Caccamo N, Salerno A, Sireci G, Dieli F.

J Immunol. 2010 Aug 1;185(3):1770-6. doi: 10.4049/jimmunol.1000966. Epub 2010 Jun 30.

32.

In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.

Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, La Mendola C, Guggino G, D'Asaro M, Orlando V, Scarpa F, Roberts A, Caccamo N, Stassi G, Dieli F, Hayday AC.

Clin Exp Immunol. 2010 Aug;161(2):290-7. doi: 10.1111/j.1365-2249.2010.04167.x. Epub 2010 May 10.

33.

V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells.

D'Asaro M, La Mendola C, Di Liberto D, Orlando V, Todaro M, Spina M, Guggino G, Meraviglia S, Caccamo N, Messina A, Salerno A, Di Raimondo F, Vigneri P, Stassi G, Fourniè JJ, Dieli F.

J Immunol. 2010 Mar 15;184(6):3260-8. doi: 10.4049/jimmunol.0903454. Epub 2010 Feb 12.

34.

Gammadelta T cell modulation in anticancer treatment.

Caccamo N, Dieli F, Meraviglia S, Guggino G, Salerno A.

Curr Cancer Drug Targets. 2010 Feb;10(1):27-36. Review.

PMID:
20088797
35.

New tools for detecting latent tuberculosis infection: evaluation of RD1-specific long-term response.

Butera O, Chiacchio T, Carrara S, Casetti R, Vanini V, Meraviglia S, Guggino G, Dieli F, Vecchi M, Lauria FN, Marruchella A, Laurenti P, Singh M, Caccamo N, Girardi E, Goletti D.

BMC Infect Dis. 2009 Nov 21;9:182. doi: 10.1186/1471-2334-9-182.

36.

Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes.

Todaro M, D'Asaro M, Caccamo N, Iovino F, Francipane MG, Meraviglia S, Orlando V, La Mendola C, Gulotta G, Salerno A, Dieli F, Stassi G.

J Immunol. 2009 Jun 1;182(11):7287-96. doi: 10.4049/jimmunol.0804288.

37.

Tuning inflammation in tuberculosis: the role of decoy receptors.

Di Liberto D, Caccamo N, Meraviglia S, Guggino G, La Manna MP, Sireci G, Salerno A, Dieli F.

Microbes Infect. 2009 Sep;11(10-11):821-7. doi: 10.1016/j.micinf.2009.05.004. Epub 2009 May 18. Review.

PMID:
19450705
38.

Analysis of Mycobacterium tuberculosis-specific CD8 T-cells in patients with active tuberculosis and in individuals with latent infection.

Caccamo N, Guggino G, Meraviglia S, Gelsomino G, Di Carlo P, Titone L, Bocchino M, Galati D, Matarese A, Nouta J, Klein MR, Salerno A, Sanduzzi A, Dieli F, Ottenhoff TH.

PLoS One. 2009;4(5):e5528. doi: 10.1371/journal.pone.0005528. Epub 2009 May 13. Retraction in: PLoS One. 2019 Sep 19;14(9):e0223028.

39.

Prevention of the post-chemotherapy relapse of tuberculous infection by combined immunotherapy.

Buccheri S, Reljic R, Caccamo N, Meraviglia S, Ivanyi J, Salerno A, Dieli F.

Tuberculosis (Edinb). 2009 Jan;89(1):91-4. doi: 10.1016/j.tube.2008.09.001. Epub 2008 Nov 5.

PMID:
18986840
40.

Advances in immunotherapy of castration-resistant prostate cancer: bisphosphonates, phosphoantigens and more.

Dieli F, Caccamo N, Meraviglia S.

Curr Opin Investig Drugs. 2008 Oct;9(10):1089-94. Review.

PMID:
18821471
41.

Role of the chemokine decoy receptor D6 in balancing inflammation, immune activation, and antimicrobial resistance in Mycobacterium tuberculosis infection.

Di Liberto D, Locati M, Caccamo N, Vecchi A, Meraviglia S, Salerno A, Sireci G, Nebuloni M, Caceres N, Cardona PJ, Dieli F, Mantovani A.

J Exp Med. 2008 Sep 1;205(9):2075-84. doi: 10.1084/jem.20070608. Epub 2008 Aug 11.

42.

Aminobisphosphonate-activated gammadelta T cells in immunotherapy of cancer: doubts no more.

Caccamo N, Meraviglia S, Scarpa F, La Mendola C, Santini D, Bonanno CT, Misiano G, Dieli F, Salerno A.

Expert Opin Biol Ther. 2008 Jul;8(7):875-83. doi: 10.1517/14712598.8.7.875 . Review.

PMID:
18549319
43.

Aminobisphosphonates as new weapons for gammadelta T Cell-based immunotherapy of cancer.

Caccamo N, Meraviglia S, Cicero G, Gulotta G, Moschella F, Cordova A, Gulotta E, Salerno A, Dieli F.

Curr Med Chem. 2008;15(12):1147-53. Review.

PMID:
18473809
44.

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, Roberts A, Buccheri S, D'Asaro M, Gebbia N, Salerno A, Eberl M, Hayday AC.

Cancer Res. 2007 Aug 1;67(15):7450-7.

45.

Decreased serum granulysin levels in childhood tuberculosis which reverse after therapy.

Di Liberto D, Buccheri S, Caccamo N, Meraviglia S, Romano A, Di Carlo P, Titone L, Dieli F, Krensky AM, Salerno A.

Tuberculosis (Edinb). 2007 Jul;87(4):322-8. Epub 2007 Mar 26.

46.

CXCR5 identifies a subset of Vgamma9Vdelta2 T cells which secrete IL-4 and IL-10 and help B cells for antibody production.

Caccamo N, Battistini L, Bonneville M, Poccia F, Fournié JJ, Meraviglia S, Borsellino G, Kroczek RA, La Mendola C, Scotet E, Dieli F, Salerno A.

J Immunol. 2006 Oct 15;177(8):5290-5.

47.

gammadelta T cells condition dendritic cells in vivo for priming pulmonary CD8 T cell responses against Mycobacterium tuberculosis.

Caccamo N, Sireci G, Meraviglia S, Dieli F, Ivanyi J, Salerno A.

Eur J Immunol. 2006 Oct;36(10):2681-90.

48.

Phenotypical and functional analysis of memory and effector human CD8 T cells specific for mycobacterial antigens.

Caccamo N, Meraviglia S, La Mendola C, Guggino G, Dieli F, Salerno A.

J Immunol. 2006 Aug 1;177(3):1780-5.

49.

In vitro effects of aminobisphosphonates on Vgamma9Vdelta2 T cell activation and differentiation.

Ferlazzo V, Sferrazza C, Caccamo N, Di Fede G, Di Lorenzo G, D'Asaro M, Meraviglia S, Dieli F, Rini G, Salerno A.

Int J Immunopathol Pharmacol. 2006 Apr-Jun;19(2):309-17.

PMID:
16831298
50.

[The evolution of didactic programs of Italian medical faculties towards an European standard].

Salerno A, Caccamo N, Meraviglia S, De Leo G.

Med Secoli. 2004;16(3):469-83. Italian.

PMID:
16247913

Supplemental Content

Loading ...
Support Center